New England Journal of Medicine· 2013Q1
Edoxaban versus Warfarin in Patients with Atrial Fibrillation
- 5,145citations
- Q1SCImago
- 2013year
Short summary
High-dose edoxaban (60 mg once daily) was noninferior to warfarin for preventing stroke or systemic embolism in atrial fibrillation patients, and significantly reduced major bleeding and cardiovascular death.
AI-generated from the title and abstract; the full text is not read.
TakeawaysIn the app
Key pointsIn the app
Ask the paperIn the app
The rest is in the Pofolia app
Takeaways, key points and questions to the paper; new summaries every day for your field. Free.
Sign in on the web to openField: Cardiology and Cardiovascular Medicine
Cardiology and Cardiovascular MedicineMedicine